Your browser doesn't support javascript.
loading
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
Nicholas C. Wu; Meng Yuan; Hejun Liu; Chang-Chun D. Lee; Xueyong Zhu; Sandhya Bangaru; Jonathan L. Torres; Tom G. Caniels; Philip J.M. Brouwer; Marit J. van Gils; Rogier W. Sanders; Andrew B. Ward; Ian A. Wilson.
Afiliación
  • Nicholas C. Wu; The Scripps Research Institute
  • Meng Yuan; The Scripps Research Institute
  • Hejun Liu; The Scripps Research Institute
  • Chang-Chun D. Lee; The Scripps Research Institute
  • Xueyong Zhu; The Scripps Research Institute
  • Sandhya Bangaru; The Scripps Research Institute
  • Jonathan L. Torres; The Scripps Research Institute
  • Tom G. Caniels; University of Amsterdam
  • Philip J.M. Brouwer; University of Amsterdam
  • Marit J. van Gils; University of Amsterdam
  • Rogier W. Sanders; University of Amsterdam
  • Andrew B. Ward; The Scripps Research Institute
  • Ian A. Wilson; The Scripps Research Institute
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-222232
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 due to structural constraints in binding the RBD (mode A). However, a small subset of IGHV3-53 antibodies to the RBD contain a longer CDR H3. Crystal structures of two IGHV3-53 neutralizing antibodies here demonstrate that a longer CDR H3 can be accommodated in a different binding mode (mode B). These two classes of IGHV3-53 antibodies both target the ACE2 receptor binding site, but with very different angles of approach and molecular interactions. Overall, these findings emphasize the versatility of IGHV3-53 in this common antibody response to SARS-CoV-2, where conserved IGHV3-53 germline-encoded features can be combined with very different CDR H3 lengths and light chains for SARS-CoV-2 RBD recognition and virus neutralization.
Licencia
cc_by
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2020 Tipo del documento: Preprint